Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

4:36 PM ET 8-K
Financial Results Ranger Energy Services, Inc. RNGR

Ranger Energy Services Financial Results

Ranger Energy Services reported Q3 2026 revenue of $162.8 million and net income of $2.5 million, while generating $20.0 million in free cash flow. During the period, the company completed the acquisition of STEP Energy Services' US coil tubing assets and declared a quarterly dividend of $0.06 per share.

Term
Q3 2026

“The past few months have marked meaningful strategic progress for Ranger. We completed the STEP coil tubing acquisition and are now positioned as the second largest coil tubing provider in the lower 48 market, expanded our contracted ECHO fleet further establishing a competitive advantage in the next generation of well-servicing equipment and navigated a challenging competitive dynamic.”

Stuart Bodden, Ranger’s Chief Executive Officer
4:36 PM ET 10-Q
Financial Results Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Q3 2026 Results: Net Loss of $32.4M, Loss Widens

Perspective Therapeutics reported a net loss of $85.4 million for the nine months ended September 30, 2026, compared to $65.6 million in the prior year period, primarily driven by increased research and development expenses. The company significantly strengthened its balance sheet through a 2026 registered offering, ending the period with $201.7 million in cash, cash equivalents, and short-term investments.

Key figure
Net loss $32.4M
4:36 PM ET 10-Q
Financial Results AbCellera Biologics Inc. ABCL

AbCellera Biologics Q3 2026 Results: Net Loss of $40.8M, Loss Narrows

AbCellera Biologics Inc. reported total revenue of $23.0 million for the nine months ended September 30, 2026, a decrease from $30.3 million in the prior year period. The company recorded a net loss of $151.3 million for the first nine months of 2026, driven by significant research and development expenses of $136.2 million as it advances its internal drug candidate pipeline, including ABCL635.

Key figure
Net loss $40.8M
4:35 PM ET 10-Q
Financial Results Bakkt, Inc. BKKT

Bakkt Q3 2026 Results: Turns Profitable, Net Income $14.3M

Bakkt, Inc. filed its 10-Q for the period ending September 30, 2026, highlighting the integration of Distributed Technologies Research Global Ltd. (DTR) and expansion into international markets. The company reported 45,126,712 shares of Class A Common Stock outstanding as of October 30, 2026, and noted significant risks related to digital asset price volatility and regulatory uncertainty.

Key figure
Net income $14.3M
4:34 PM ET 10-Q
Financial Results Tg Therapeutics, Inc. TGTX

Tg Therapeutics Q3 2026 Results: Net Income $55.5M, Down 85.8% YoY

TG Therapeutics is focused on the commercialization of BRIUMVI for relapsing forms of multiple sclerosis and the development of its subcutaneous formulation and azer-cel. The company has a history of losses but is utilizing its commercial infrastructure to expand market acceptance while managing significant debt obligations and clinical trial expenses.

Key figure
Net income $55.5M · -85.8% YoY
4:34 PM ET 10-Q
Financial Results Jbs N.V. JBS

Jbs Q3 2026 Results: Net Income $189M, Down 70.7% YoY

For the nine-month period ended September 30, 2026, JBS N.V. reported net revenue of $68.2 billion, a 8.1% increase over the prior year, though net income fell significantly to $334.3 million from $1.79 billion. The decline was driven by higher cost of sales and increased net finance expenses, resulting in basic earnings per share of $0.26 compared to $1.45 in 2025.

Key figure
Net income $189M · -70.7% YoY
4:34 PM ET 8-K
Financial Results Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Financial Results

Perspective Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting a cash position of $202 million which is expected to fund operations into 2028. The company reported a net loss of $24.7 million for the quarter and provided clinical updates on its lead radiopharmaceutical programs, including bamzireotide navoxetan and lapemelanotide zapixetar.

Term
Q3 2026

“We have presented clinical data that demonstrated the potential of delivering alpha radiation via our proprietary targeted oncology platform. With encouraging clinical findings observed to date that further support the best‑in‑class potential of bamzireotide, continued progress across two additional programs targeting melanoma and FAP-α-positive solid tumors, and investments in our manufacturing capabilities, we are well-positioned to lead the development of the field.”

Thijs Spoor, Perspective’s Chief Executive Officer
4:34 PM ET 10-Q
Financial Results Puma Biotechnology, Inc. PBYI

Puma Biotechnology Q3 2026 Results: Net Income $5.96M, Down 32.7% YoY

Puma Biotechnology reported total revenue of $55.1 million for the third quarter of 2026, driven primarily by NERLYNX product sales. While the company remained profitable with a net income of $6.0 million, this was a decrease from $8.8 million in the prior year's third quarter due to higher research and development expenses.

Key figure
Net income $5.96M · -32.7% YoY
4:34 PM ET 10-Q
Financial Results InfuSystem Holdings, Inc INFU

InfuSystem Holdings Q3 2026 Results: Net Income $3.16M, Up 39.7% YoY

InfuSystem Holdings, Inc. reported net revenues of $37.6 million for the third quarter of 2026, a 3% increase year-over-year, with net income rising to $3.2 million compared to $2.3 million in the prior year period. The company demonstrated improved operational efficiency with operating income growing 24.5% to $4.7 million, supported by a reduction in cost of revenues and strong gross profit margins.

Key figure
Net income $3.16M · +39.7% YoY
4:33 PM ET 10-Q
Financial Results Xenon Pharmaceuticals Inc. XENE

Xenon Pharmaceuticals Q3 2026 Results: Net Loss of $110M, Loss Widens

Xenon Pharmaceuticals reported a net loss of $323.5 million for the nine months ended September 30, 2026, compared to $240.6 million in the prior year, driven by increased R&D spending on its lead candidate azetukalner. The company significantly strengthened its balance sheet, ending the period with $1.15 billion in cash, cash equivalents, and marketable securities following substantial common share issuances.

Key figure
Net loss $110M
4:33 PM ET 10-Q
Financial Results Office Properties Income Trust OPI

Office Properties Income Trust Q3 2026 Results: Net Loss of $48.9M

Office Properties Income Trust reported a net loss of $45.8 million for the third quarter of 2026, following its emergence from Chapter 11 bankruptcy on June 18, 2026. The company's financial statements are now presented using 'Successor' and 'Predecessor' accounting, reflecting a significant restructuring of its balance sheet and debt obligations.

Key figure
Net loss $48.9M
4:33 PM ET 10-Q
Financial Results Praxis Precision Medicines, Inc. PRAX

Praxis Precision Medicines Q3 2026 Results: Net Loss of $94.2M, Loss Widens

Praxis Precision Medicines reported a net loss of $94.2 million for the third quarter of 2026, compared to $73.9 million in the prior year period, driven by increased general and administrative expenses. The company significantly strengthened its balance sheet through a follow-on public offering, ending September 30, 2026, with $1.31 billion in total assets including $745.3 million in cash and marketable securities.

Key figure
Net loss $94.2M
4:33 PM ET 10-Q
Financial Results Select Water Solutions, Inc. WTTR

Select Water Solutions Q3 2026 Results: Net Income $20.6M, Up 668.1% YoY

Select Water Solutions reported a significant increase in total revenue to $412.2 million for the third quarter of 2026, up from $322.2 million in the prior year. Net income attributable to the company rose to $20.6 million ($0.16 per diluted Class A share) compared to $2.7 million in the same period of 2025, driven by strong performance in the Water Infrastructure and Water Services segments.

Key figure
Net income $20.6M · +668.1% YoY
4:33 PM ET 10-Q
Financial Results James River Group Holdings, Inc. JRVR

James River Group Holdings Q3 2026 Results: Net Loss of $187M

James River Group Holdings, Inc. reported a decrease in total invested assets to $1.68 billion as of September 30, 2026, compared to $1.70 billion at year-end 2025. The company completed a domestication from Bermuda to Delaware in late 2025 and is currently classified as an accelerated filer with 46,249,038 shares of common stock outstanding.

Key figure
Net loss $187M
4:33 PM ET 10-Q
Financial Results Take Two Interactive Software Inc TTWO ▶ Call

Take Two Interactive Software Q2 2026 Results: Net Loss of $54M, Loss Narrows

Take-Two Interactive reported a net loss of $54.0 million for the quarter ended September 30, 2026, an improvement from a $133.9 million loss in the prior year. Total net revenue decreased to $1.50 billion from $1.77 billion, while the company maintained a strong liquidity position with $1.15 billion in cash and cash equivalents.

Key figure
Net loss $54M
4:32 PM ET 10-Q
Financial Results Orasure Technologies Inc OSUR

Orasure Technologies Q3 2026 Results: Net Loss of $13.1M, Loss Narrows

OraSure Technologies reported a net loss of $13.1 million for Q3 2026, a slight improvement from the $13.7 million loss in the prior year period, despite a 14% increase in total net revenues to $30.9 million. For the first nine months of 2026, the company significantly reduced its operating loss to $30.8 million, aided by a $22.5 million gain from the change in fair value of acquisition-related contingent consideration.

Key figure
Net loss $13.1M
4:32 PM ET 10-Q
Financial Results Ispire Technology Inc. ISPR

Ispire Technology Q1 2026 Results: Net Loss of $6.44M, Loss Widens

For the quarter ended September 30, 2026, Ispire Technology Inc. reported revenue of $27.54 million, a decrease from $30.35 million in the prior year period. The company experienced a net loss for the quarter, contributing to an accumulated deficit of $87.71 million and a total stockholders' deficit of $34.85 million.

Key figure
Net loss $6.44M
4:32 PM ET 10-Q
Financial Results Abeona Therapeutics Inc. ABEO

Abeona Therapeutics Q3 2026 Results: Net Loss of $4.81M, Loss Narrows

Abeona Therapeutics reported a decrease in cash and short-term investments to $134.9 million as of September 30, 2026, compared to $191.4 million at year-end 2025. The company is focused on the commercialization of ZEVASKYN and the development of ABO-801, while noting a private placement transaction announced on November 9, 2026.

Key figure
Net loss $4.81M
4:32 PM ET 10-Q
Financial Results Zeta Global Holdings Corp. ZETA

Zeta Global Holdings Q3 2026 Results: Turns Profitable, Net Income $38.3M

Zeta Global Holdings Corp. reported its third-quarter 2026 results, noting its status as a large accelerated filer with 255,458,977 total shares outstanding as of November 2, 2026. The filing highlights risks related to long sales cycles, dependence on super-scaled customers, and potential fluctuations in revenue during election years.

Key figure
Net income $38.3M
4:32 PM ET 8-K
Financial Results Viant Technology Inc. DSP

Viant Technology Financial Results

Viant Technology reported Q3 2026 financial results with revenue increasing 29% year-over-year to $110.4 million, driven by a 40% increase in Connected TV (CTV) advertiser spend. Alongside the results, the company announced a $50 million increase to its stock repurchase program and the acquisition of Waymark, a generative AI video creative platform.

Term
Q3 2026

“Viant delivered record third quarter results, exceeding the high-end of our guidance range for contribution ex-TAC and adjusted EBITDA. Our ongoing momentum can be directly attributed to our recent evolution into a comprehensive advertising intelligence company.”

Tim Vanderhook, Co-Founder and CEO

“By combining Waymark's generative AI with our audience, content, and attention intelligence, we can empower advertisers of all sizes to produce audience tailored, contextually relevant, and attention-optimized creatives in minutes and at a fraction of traditional costs.”

Tim Vanderhook, Co-Founder and CEO
4:32 PM ET 8-K
Financial Results Jbs N.V. JBS

Jbs Financial Results

JBS N.V. reported third quarter 2026 net sales of $22.7 billion, a 1% increase year-over-year, though net income fell significantly to $164 million ($0.15 per share). The company faced a challenging operating environment that saw Adjusted EBITDA drop 36% to $1.18 billion and leverage increase to 3.54x. Management noted that while JBS Brazil was impacted by lower China exports, the North American beef segment returned to profitability by the end of the quarter.

Term
Q3 2026

“In 3Q26, JBS faced a more challenging operating environment across several of its business units. The weaker operating performance resulted in an increase in leverage to 3.54x. JBS Beef North America returned to positive adjusted EBITDA under US GAAP, supported by better market conditions and continued improvements in operational integration, commercial execution and industrial efficiency.”

Gilberto Tomazoni — Global CEO
4:32 PM ET 8-K/A
Financial Results Tecnoglass Holdings Inc. TGLS

Tecnoglass Holdings Financial Results

Tecnoglass Holdings Inc. filed an amendment to its Q3 2026 earnings report to correct the accounting for deferred income taxes related to treasury stock fair value changes. The non-cash correction increased the income tax provision by $6.0 million, resulting in a decrease in net income from $22.8 million to $16.7 million for the quarter. The adjustment had no impact on the company's reported revenue, operating income, or Adjusted EBITDA.

Term
Q3 2026
4:32 PM ET 10-Q
Financial Results Tecnoglass Holdings Inc. TGLS

Tecnoglass Holdings Q3 2026 Results: Net Income $16.7M, Down 64.6% YoY

Tecnoglass Holdings Inc. reported total operating revenues of $854.9 million for the nine months ended September 30, 2026, compared to $738.3 million in the prior year period. Net income for the first nine months of 2026 was $73.2 million, a decrease from $133.5 million in 2025, primarily driven by higher cost of sales and operating expenses.

Key figure
Net income $16.7M · -64.6% YoY
4:32 PM ET 10-Q
Financial Results Hinge Health, Inc. HNGE

Hinge Health Q3 2026 Results: Turns Profitable, Net Income $57.4M

Hinge Health, Inc. filed its Form 10-Q for the quarter ended September 30, 2026, reporting a dual-class common stock structure with 68,485,043 Class A and 12,786,259 Class B shares outstanding. The company highlights its expansion into Migraine and Gastrointestinal care programs and the acquisition of Cylinder Health, Inc., while cautioning that it has a history of net losses and may not achieve profitability.

Key figure
Net income $57.4M
4:31 PM ET 8-K
Financial Results FiscalNote Holdings, Inc. NOTE

FiscalNote Holdings Financial Results

FiscalNote reported Q3 2026 revenue of $18.7 million and a significantly narrowed net loss of $5.9 million compared to $24.9 million in the prior year. The company achieved an Adjusted EBITDA of $3.6 million, driven by cost efficiencies and the divestiture of its FrontierView business to sharpen focus on core AI-driven policy intelligence.

Term
Q3 2026

“Our focus this quarter was on maturing product delivery while continuing to realize the cost efficiencies now showing up in our profitability. Our go-forward priority is on the assets our customers can’t get anywhere else: our decades of policy journalism and our deep bank of proprietary legislative and regulatory data, delivered through PolicyNote and our PolicyNote APIs and MCP integrations which embed our intelligence directly into our customers’ agentic workflows.”

Key Compton, CEO and President of FiscalNote
4:30 PM ET 10-Q
Financial Results Babcock & Wilcox Enterprises, Inc. BW

Babcock & Wilcox Enterprises Q3 2026 Results: Net Income $93.9M, Up 167.6% YoY

Babcock & Wilcox Enterprises reported a significant increase in revenues for the nine months ended September 30, 2026, reaching $824.9 million compared to $426.7 million in the prior year period. The company successfully redeemed its 6.50% and 8.125% Senior Notes during 2026 and 2025, respectively, while issuing new 8.75% Senior Secured Notes due 2030.

Key figure
Net income $93.9M · +167.6% YoY
4:30 PM ET 10-Q
Financial Results PubMatic, Inc. PUBM

PubMatic Q3 2026 Results: Turns Profitable, Net Income $5.54M

PubMatic reported revenue of $79.6 million for the third quarter of 2026, a 17% increase year-over-year, and returned to profitability with a net income of $5.5 million. Despite the quarterly gain, the company recorded a net loss of $8.2 million for the first nine months of 2026, though this was a significant improvement from the $21.1 million loss in the prior year period.

Key figure
Net income $5.54M
4:28 PM ET 10-Q
Financial Results Trevi Therapeutics, Inc. TRVI

Trevi Therapeutics Q3 2026 Results: Net Loss of $21.5M, Loss Widens

Trevi Therapeutics reported a net loss of $52.4 million for the nine months ended September 30, 2026, compared to $34.4 million in the prior year, primarily driven by increased R&D expenses for its Haduvio clinical trials. The company significantly strengthened its balance sheet through a common stock offering, ending the period with $299.4 million in cash, cash equivalents, and marketable securities.

Key figure
Net loss $21.5M
4:28 PM ET 8-K
Financial Results Green Dot Corp GDOT

Green Dot Financial Results

Green Dot Corporation reported Q3 2026 financial results with total operating revenues of $601.1 million, a 21% increase year-over-year. The company reported a GAAP net loss of $7.4 million, showing significant improvement from the $30.8 million loss in the prior year period. Management highlighted growth in the embedded finance space as the company prepares for its pending acquisition by Smith Ventures and CommerceOne.

“Green Dot delivered another strong quarter of growth and efficiency, which were bolstered by our continued efforts to improve operations, optimize our balance sheet and capitalize on increasing demand and opportunity in the embedded finance space.”

William I Jacobs, Chairman and Chief Executive Officer

“I am proud of the team’s continued focus and commitment to our customers and partners, particularly as we prepare for our next chapter with Smith Ventures and CommerceOne.”

William I Jacobs, Chairman and Chief Executive Officer
4:27 PM ET 10-K
Financial Results Emerson Electric Co EMR

Emerson Electric FY 2026 Results: Net Income $2.69B, Up 18.5% YoY

Emerson Electric Co. reported fiscal 2026 net sales of $19.0 billion, a 5% increase over the prior year, with net earnings from continuing operations rising 19% to $2.69 billion. The company transitioned to mark-to-market accounting for pension plans and reported adjusted diluted EPS of $6.59, reflecting strong operating performance and sales growth.

Key figure
Net income $2.69B · +18.5% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.